Managing mitral regurgitation: focus on the MitraClip device
J Trent Magruder,1 Todd C Crawford,1 Joshua C Grimm,1 Joseph L Fredi,2 Ashish S Shah3 1Division of Cardiac Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, 2Department of Medicine, Division of Cardiovascular Medicine, Vanderbilt University Medical Center, 3Department of Cardiac S...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2016-04-01
|
Series: | Medical Devices: Evidence and Research |
Subjects: | |
Online Access: | https://www.dovepress.com/managing-mitral-regurgitation-focus-on-the-mitraclip-device-peer-reviewed-article-MDER |
_version_ | 1818982780843851776 |
---|---|
author | Magruder JT Crawford TC Grimm JC Fredi JL Shah AS |
author_facet | Magruder JT Crawford TC Grimm JC Fredi JL Shah AS |
author_sort | Magruder JT |
collection | DOAJ |
description | J Trent Magruder,1 Todd C Crawford,1 Joshua C Grimm,1 Joseph L Fredi,2 Ashish S Shah3 1Division of Cardiac Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, 2Department of Medicine, Division of Cardiovascular Medicine, Vanderbilt University Medical Center, 3Department of Cardiac Surgery, Vanderbilt University School of Medicine, Nashville, TN, USA Abstract: Based on the principle of surgical edge-to-edge mitral valve repair (MVR), the MitraClip percutaneous MVR technique has emerged as a minimally invasive option for MVR. This catheter-based system has been widely demonstrated to be safe, although inferior to surgical MVR. Studies examining patients with ≥3+ mitral regurgitation (MR) show that, for all patients treated, freedom from death, surgery, or MR ≥3+ is in the 75%–80% range 1 year following MitraClip implantation. Despite its inferiority to surgical therapy, in high-risk surgical patients, data suggest that the MitraClip system can be employed safely and that it can result in symptomatic improvement in the majority of patients, while not precluding future surgical options. MitraClip therapy also appears to reduce heart failure readmissions in the high-risk cohort, which may lead to an economic benefit. Ongoing study is needed to clarify the impact of percutaneous mitral valve clipping on long-term survival in high-risk populations, as well as its role in other patient populations, such as those with functional MR. Keywords: mitral clips, mitral regurgitation, cardiac surgery, percutaneous, transcatheter |
first_indexed | 2024-12-20T17:52:40Z |
format | Article |
id | doaj.art-bcf5285a7df549128c29d5cbcbbf677b |
institution | Directory Open Access Journal |
issn | 1179-1470 |
language | English |
last_indexed | 2024-12-20T17:52:40Z |
publishDate | 2016-04-01 |
publisher | Dove Medical Press |
record_format | Article |
series | Medical Devices: Evidence and Research |
spelling | doaj.art-bcf5285a7df549128c29d5cbcbbf677b2022-12-21T19:30:49ZengDove Medical PressMedical Devices: Evidence and Research1179-14702016-04-012016Issue 1536026388Managing mitral regurgitation: focus on the MitraClip deviceMagruder JTCrawford TCGrimm JCFredi JLShah ASJ Trent Magruder,1 Todd C Crawford,1 Joshua C Grimm,1 Joseph L Fredi,2 Ashish S Shah3 1Division of Cardiac Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, 2Department of Medicine, Division of Cardiovascular Medicine, Vanderbilt University Medical Center, 3Department of Cardiac Surgery, Vanderbilt University School of Medicine, Nashville, TN, USA Abstract: Based on the principle of surgical edge-to-edge mitral valve repair (MVR), the MitraClip percutaneous MVR technique has emerged as a minimally invasive option for MVR. This catheter-based system has been widely demonstrated to be safe, although inferior to surgical MVR. Studies examining patients with ≥3+ mitral regurgitation (MR) show that, for all patients treated, freedom from death, surgery, or MR ≥3+ is in the 75%–80% range 1 year following MitraClip implantation. Despite its inferiority to surgical therapy, in high-risk surgical patients, data suggest that the MitraClip system can be employed safely and that it can result in symptomatic improvement in the majority of patients, while not precluding future surgical options. MitraClip therapy also appears to reduce heart failure readmissions in the high-risk cohort, which may lead to an economic benefit. Ongoing study is needed to clarify the impact of percutaneous mitral valve clipping on long-term survival in high-risk populations, as well as its role in other patient populations, such as those with functional MR. Keywords: mitral clips, mitral regurgitation, cardiac surgery, percutaneous, transcatheterhttps://www.dovepress.com/managing-mitral-regurgitation-focus-on-the-mitraclip-device-peer-reviewed-article-MDERmitral clipsmitral regurgitationcardiac surgerypercutaneous |
spellingShingle | Magruder JT Crawford TC Grimm JC Fredi JL Shah AS Managing mitral regurgitation: focus on the MitraClip device Medical Devices: Evidence and Research mitral clips mitral regurgitation cardiac surgery percutaneous |
title | Managing mitral regurgitation: focus on the MitraClip device |
title_full | Managing mitral regurgitation: focus on the MitraClip device |
title_fullStr | Managing mitral regurgitation: focus on the MitraClip device |
title_full_unstemmed | Managing mitral regurgitation: focus on the MitraClip device |
title_short | Managing mitral regurgitation: focus on the MitraClip device |
title_sort | managing mitral regurgitation focus on the mitraclip device |
topic | mitral clips mitral regurgitation cardiac surgery percutaneous |
url | https://www.dovepress.com/managing-mitral-regurgitation-focus-on-the-mitraclip-device-peer-reviewed-article-MDER |
work_keys_str_mv | AT magruderjt managingmitralregurgitationfocusonthemitraclipdevice AT crawfordtc managingmitralregurgitationfocusonthemitraclipdevice AT grimmjc managingmitralregurgitationfocusonthemitraclipdevice AT fredijl managingmitralregurgitationfocusonthemitraclipdevice AT shahas managingmitralregurgitationfocusonthemitraclipdevice |